Custom Search

Brand Name(s): Oporia
CAS nē: 180916-16-9
(la so fox ih feen)

What is Lasofoxifene?

Lasofoxifene (OporiaŽ) is a selective estrogen receptor modulator (SERM) under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

Osteoporosis affects some 8 million American women. An additional 22 million women are estimated to have low bone mass, placing them at increased risk of osteoporosis. In the U.S., osteoporosis is responsible for more than 1.5 million fractures per year.

Vaginal dryness becomes increasingly more common throughout the menopausal transition. SERMs may offer benefits beyond just the bone effects provided by other treatment options, such as bisphosphonates.

See more Product Info

Latest News

Ligand partner Pfizer files NDA for Fablyn

Ligand Pharmaceuticals has announced that its partner Pfizer has submitted a new drug application...

[more]

Oporia (lasofoxifene) - Investigational serm for the prevention and treatment of osteoporosis

The product of a joint development programme between Pfizer and Ligand Pharmaceuticals, Oporia...

[more]

Pfizer Submits SNDA to Expand Potential Market for Lasofoxifene

Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that Pfizer has confirmed a...

[more]

Lasofoxifene: CP 336156, CP-336156

Lasofoxifene [CP 336156] is a potent, nonsteroidal, tissue-selective estrogen receptor modulator...

[more]

Investigational SERM increased lumbar spine BMD by 2%

The next generation selective-estrogen receptor modulator lasofoxifene increased vertebral bone...

[more]

Use of this site is subject to the following terms of use